LGDN:FRA
Ligand Pharmaceuticals Inc
€190.00
0.00%
(0.00) 1D
බක් 24, 22.00.00 ග්රිමවේ+2 · EUR
search
සියලු සංකේත
1D
5D
1M
6M
YTD
1Y
5Y
උපරි
| සංකේතය | මිල | වෙනස් කිරීම | % වෙනස |
|---|
insights_autoLGDN සඳහා ඉහළම ඇතුළාන්තයන් උත්පාදනය කරමින්...
විවෘත කරන්න
€192.00
ඉහළ
€192.00
පහළ
€190.00
වෙ.පො ප්රාග්ධනය
බි4.63
දළ පරිමාව
3.00
හඬ පරිමාණය
0.00
සති-52 ඉහළ
€195.00
සති-52 පහළ
€87.00
සේවකයින් ගණන
47
පුවත් සහ කථා
වෙබය හරහා මූලාශ්ර වෙතින්
Cổng thông tin điện tử tỉnh Lào Cai
·
සති 1කට පෙර
What chart pattern is Ligand (LGND) Stock forming | Price at $206.12, Up 0.59% - Verified Stock Signals
පැතිකඩ
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
Ligand Pharmaceuticals Inc ගැන
AI අන්තර්ගතයේ වැරදි ඇතුළත් විය හැක. තව දැන ගන්න